FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2130684080> ?p ?o ?g. }

• W2130684080 endingPage "2090" @default.
• W2130684080 startingPage "2082" @default.
• W2130684080 abstract "Patients with type 2 diabetes mellitus are routinely treated with combinations of glucose-lowering agents. The adverse event (AE) profile and effects on glycemic control have not been assessed for the glucagon-like peptide-1 receptor agonist exenatide once weekly in combination with a thiazolidinedione (TZD) with or without metformin.This study was conducted to examine the long-term safety profile and changes in glycemic control and weight for exenatide once weekly with TZD with or without metformin in patients with type 2 diabetes mellitus over 2 years.In this single-arm, open-label trial with treatment up to 104 or 117 weeks, patients received 2 mg exenatide once weekly while continuing treatment with a TZD with or without metformin. Patients were either exenatide-naïve before this study or had previously received exenatide twice daily, which was discontinued on initiating exenatide once weekly. Patients were on a stable dosage of TZD (rosiglitazone or pioglitazone) and, if applicable, metformin. Treatment-emergent AEs were defined as those first occurring or worsening post baseline. Descriptive statistics were used for absolute and change-from-baseline data, and a one-sample t test for within-group change in glycosylated hemoglobin (HbA(1c)).Of 134 patients in the intent-to-treat population (baseline mean [SD] HbA(1c),7.2% [1.0%]), 44 were exenatide-naïve (baseline HbA(1c), 7.8% [1.0%]) and 90 switched from exenatide twice daily (baseline HbA(1c), 7.0% [0.8%]). Of intent-to-treat patients, 106 (79%) completed the final treatment visit (week 104 or week 117). The most common AEs were nausea (17% of patients) and injection-site nodule (12% of patients). Serious AEs were reported in 14% of patients and 5% withdrew because of a treatment-emergent AE. No identifiable pattern of serious AEs was observed. There were 4 reports of edema and no reports of heart failure. No major hypoglycemia was reported; minor hypoglycemia was reported in 4% of patients. Exenatide-naïve patients experienced mean (SE) HbA(1c) reductions of -0.7% (0.2%) and weight reductions of -2.7 (0.8) kg, whereas patients with prior exposure to exenatide twice daily experienced a reduction of -0.4% (0.1%) in HbA(1c) and no change in weight.Adverse events over 2 years were consistent with the reported safety profiles of exenatide once weekly and TZDs. Exenatide-naïve patients experienced improvements in HbA(1c) and weight, while patients with the benefit of prior exenatide therapy experienced an additional reduction from baseline in HbA(1c) and no additional change in weight after 2 years. ClinicalTrials.gov identifier: NCT00753896." @default.
• W2130684080 created "2016-06-24" @default.
• W2130684080 creator A5000291054 @default.
• W2130684080 creator A5012995950 @default.
• W2130684080 creator A5018620186 @default.
• W2130684080 creator A5019150153 @default.
• W2130684080 creator A5046196398 @default.
• W2130684080 creator A5062021087 @default.
• W2130684080 date "2012-10-01" @default.
• W2130684080 modified "2023-09-30" @default.
• W2130684080 title "Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With a Thiazolidinedione Alone or in Combination With Metformin for 2 Years" @default.
• W2130684080 cites W1982311681 @default.
• W2130684080 cites W2026804284 @default.
• W2130684080 cites W2036939737 @default.
• W2130684080 cites W2043900831 @default.
• W2130684080 cites W2050826565 @default.
• W2130684080 cites W2066046508 @default.
• W2130684080 cites W2070862506 @default.
• W2130684080 cites W2072691447 @default.
• W2130684080 cites W2083357334 @default.
• W2130684080 cites W2083477872 @default.
• W2130684080 cites W2086177834 @default.
• W2130684080 cites W2098289172 @default.
• W2130684080 cites W2105407506 @default.
• W2130684080 cites W2107949845 @default.
• W2130684080 cites W2108646121 @default.
• W2130684080 cites W2111645882 @default.
• W2130684080 cites W2127125241 @default.
• W2130684080 cites W2129934471 @default.
• W2130684080 cites W2130478319 @default.
• W2130684080 cites W2131964379 @default.
• W2130684080 cites W2138077952 @default.
• W2130684080 cites W2139485303 @default.
• W2130684080 cites W2160001758 @default.
• W2130684080 cites W2167984392 @default.
• W2130684080 cites W2172193326 @default.
• W2130684080 cites W4236897356 @default.
• W2130684080 cites W4292528167 @default.
• W2130684080 doi "https://doi.org/10.1016/j.clinthera.2012.09.007" @default.
• W2130684080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23031623" @default.
• W2130684080 hasPublicationYear "2012" @default.
• W2130684080 type Work @default.
• W2130684080 sameAs 2130684080 @default.
• W2130684080 citedByCount "19" @default.
• W2130684080 countsByYear W21306840802012 @default.
• W2130684080 countsByYear W21306840802013 @default.
• W2130684080 countsByYear W21306840802014 @default.
• W2130684080 countsByYear W21306840802015 @default.
• W2130684080 countsByYear W21306840802016 @default.
• W2130684080 countsByYear W21306840802017 @default.
• W2130684080 countsByYear W21306840802018 @default.
• W2130684080 countsByYear W21306840802021 @default.
• W2130684080 countsByYear W21306840802023 @default.
• W2130684080 crossrefType "journal-article" @default.
• W2130684080 hasAuthorship W2130684080A5000291054 @default.
• W2130684080 hasAuthorship W2130684080A5012995950 @default.
• W2130684080 hasAuthorship W2130684080A5018620186 @default.
• W2130684080 hasAuthorship W2130684080A5019150153 @default.
• W2130684080 hasAuthorship W2130684080A5046196398 @default.
• W2130684080 hasAuthorship W2130684080A5062021087 @default.
• W2130684080 hasConcept C126322002 @default.
• W2130684080 hasConcept C134018914 @default.
• W2130684080 hasConcept C197934379 @default.
• W2130684080 hasConcept C2776923340 @default.
• W2130684080 hasConcept C2777180221 @default.
• W2130684080 hasConcept C2778384471 @default.
• W2130684080 hasConcept C2779284873 @default.
• W2130684080 hasConcept C2779306644 @default.
• W2130684080 hasConcept C2780152017 @default.
• W2130684080 hasConcept C2780323712 @default.
• W2130684080 hasConcept C2780473172 @default.
• W2130684080 hasConcept C2780533449 @default.
• W2130684080 hasConcept C2908647359 @default.
• W2130684080 hasConcept C2910068830 @default.
• W2130684080 hasConcept C555293320 @default.
• W2130684080 hasConcept C71924100 @default.
• W2130684080 hasConcept C99454951 @default.
• W2130684080 hasConceptScore W2130684080C126322002 @default.
• W2130684080 hasConceptScore W2130684080C134018914 @default.
• W2130684080 hasConceptScore W2130684080C197934379 @default.
• W2130684080 hasConceptScore W2130684080C2776923340 @default.
• W2130684080 hasConceptScore W2130684080C2777180221 @default.
• W2130684080 hasConceptScore W2130684080C2778384471 @default.
• W2130684080 hasConceptScore W2130684080C2779284873 @default.
• W2130684080 hasConceptScore W2130684080C2779306644 @default.
• W2130684080 hasConceptScore W2130684080C2780152017 @default.
• W2130684080 hasConceptScore W2130684080C2780323712 @default.
• W2130684080 hasConceptScore W2130684080C2780473172 @default.
• W2130684080 hasConceptScore W2130684080C2780533449 @default.
• W2130684080 hasConceptScore W2130684080C2908647359 @default.
• W2130684080 hasConceptScore W2130684080C2910068830 @default.
• W2130684080 hasConceptScore W2130684080C555293320 @default.
• W2130684080 hasConceptScore W2130684080C71924100 @default.
• W2130684080 hasConceptScore W2130684080C99454951 @default.
• W2130684080 hasIssue "10" @default.
• W2130684080 hasLocation W21306840801 @default.
• W2130684080 hasLocation W21306840802 @default.
• W2130684080 hasOpenAccess W2130684080 @default.

• next